Peripheral T‐cell lymphoma (PTCL) is a heterogeneous group of aggressive non‐Hodgkin
lymphomas typically associated with poor prognosis. Most patients with PTCL receive …

Purpose Romidepsin is a structurally unique, potent class 1 selective histone deacetylase
inhibitor. The primary objective of this international, pivotal, single-arm, phase II trial was to …

Abstract Abstract 3641 Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous
group of lymphoproliferative disorders, and most subtypes have a poor prognosis even with …

Background Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone
deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of …

Peripheral T-cell lymphomas (PTCLs) are a rare, heterogeneous group of T-cell–or natural
killer cell–derived non-Hodgkin lymphomas. The majority of patients with PTCL experience …

Background Achievement of durable responses in patients with relapsed/refractory
peripheral T cell lymphoma (PTCL) is challenging with current therapies, and there are few …

Romidepsin (depsipeptide or FK228) is a histone deacetylase inhibitor, one of a new class
of agents active in T-cell lymphoma. A phase 2 trial was conducted in cutaneous (CTCL) and …

Abstract Abstract 1657 Poster Board I-683 Background The histone deacetylase (HDAC)
inhibitors are a class of epigenetic agents undergoing clinical testing. HDAC inhibitors …

Background: Peripheral T-cell lymphoma (PTCL) is an aggressive form of non-Hodgkin
lymphoma (NHL) that is typically associated with a poor prognosis. Romidepsin is a histone …

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas
associated with poor prognosis in most subtypes. Diagnosis of this rare disease by expert …